LEAVO Health Economic and Decision Modelling Analysis Plan (HEDMAP)

This is the Health Economic and Decision Modelling Analysis Plan (HEDMAP) and addendum for the LEAVO Study. The LEAVO study is a multicentre double-masked randomised non-inferiority clinical trial comparing the clinical and cost-effectiveness of intravitreal ranibizumab (Lucentis), aflibercept (Eylea) and bevacizumab (Avastin) for Macular Oedema due to Central Retinal Vein Occlusion. This HEDMAP document outlines the planned procedures for conduction the Health Economic Evaluation sub-study of the LEAVO project. The health economic model structure for assessing the long-term cost-effectiveness of these treatments is provided as an addendum to this document.